BioSpace News Archive

Xenon Pharmaceuticals Inc. today announced that the company will present at the 22nd Annual Needham Virtual Healthcare Conference taking place April 17-20, 2023.

Hyloris Pharmaceuticals SA, a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, announces that its partner AFT Pharmaceuticals has submitted a response to the Food & Drug Administration.

GC Genome Corporation, a leading diagnostics company, announced that the company will present data showcasing the deep learning algorithm that detects and classifies multi-cancer using methylation information and genomic data at the American Association for Cancer Research Annual Meeting 2023 in Orlando, Florida.

Cambrium, a leading German start-up focused on the application of generative AI to protein design and synthesis, and Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, announced the successful completion of their collaboration.

United Therapeutics Corporation announced that recent research across its development portfolio will be presented at the International Society for Heart and Lung Transplantation 43rd Annual Meeting and Scientific Sessions in Denver, Colorado on April 19-22, 2023, and at the American Thoracic Society International Conference in Washington, D.C. on May 19-24, 2023.

Ampio Pharmaceuticals, Inc. released the following letter to stockholders from its Chairman, Kevin Buchi and Chief Executive Officer, Mike Martino.

Ondine Biomedical Inc. presented detailed results from its US Phase 2 BENEFIT-aPDT clinical trial to the 33rd European Congress of Clinical Microbiology and Infectious Diseases in Copenhagen, Denmark.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company has secured $450 million in committed financing from funds managed by Pharmakon Advisors, LP. BioCryst has elected to draw $300 million of the $450 million available to the company on the closing date.

Clearside Biomedical, Inc. (Nasdaq: CLSD) announced today plans for ODYSSEY, a randomized, double-masked, parallel-group, active-controlled, multi-center Phase 2b clinical trial of CLS-AX (axitinib injectable suspension) using suprachoroidal delivery in neovascular age-related macular degeneration (wet AMD).

Plus Therapeutics, Inc. today announced the completion of Cohort 3 of the ReSPECT-LM Phase 1/2a dose-escalation clinical trial of rhenium (186Re) obisbemeda for the treatment of leptomeningeal metastases (LM) from solid tumors less than one month since its initiation, demonstrating rapid enrollment.